Nucleai nabs $6.5m Series A

Nucleai, a provider of a AI-powered precision oncology technology, has raised $6.5 million in Series A funding.

Nucleai, a provider of a AI-powered precision oncology technology, has raised $6.5 million in Series A funding. Debiopharm led the round with participation from return backers Vertex Ventures and Grove Ventures.

Source: Press Release